MindRank

Banking

MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity

December 26, 2022
Photo of MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity

[ad_1] SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire/ — MindRank, an artificial intelligence (AI)-empowered drug discovery company, announces today…

Read More »
Back to top button
Close